Whereas the subgroups meta-analysis of studies with cut off value of high expression (HR: 1.28; 95% CI: 0.66–2.48) as well as IRS expression (HR: 1.56; 95% CI: 0.63–3.85) illustrated no correlation of ALDH expression with DFS/PFS in ovarian cancer patients, and heterogeneity was observed using the random effects model (high expression of ANRIL: I2 = 74%, P = 0.02; IRS expression of ANRIL: I2 = 75%, P = 0.05). Here, CDKN2B-AS1 is linked to ovarian cancer.